Solvent-Dependent Photophysics and Reactivity of Monomeric and Dimeric 4-Amino-1,8-Naphthalimides
Publication: The Journal of Physical Chemistry A
Synthetic platform for mono-functionalised tridentate macrocycles as key precursors of mechanically-linked macromolecular systems
Publication: Organic Chemistry Frontiers
US FDA approved drugs from 2015-June 2020-A perspective
Publication: Journal of Medicinal Chemistry
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia
Publication: Leukemia
A novel reactor configuration for continuous virus inactivation
Publication: Biochemical Engineering Journal
Palladium‐Catalyzed Reductive Carbonylation of (Hetero) Aryl Halides and Triflates Using Cobalt Carbonyl as CO Source
Publication: Europen Journal of Organic Chemistry
Lead Optimization of a Pyrrole-Based Dihydroorotate
Publication: Journal of Medicinal Chemistry
How Syngene helped develop the world’s first drug for a rare disease affecting children
Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.
Accelerating PROTAC programs to drug the “undruggable”
Syngene offers expertise in all aspects of PROTACs – from designing of small molecules to their synthesis, lead optimization, and ultimate candidate delivery at an accelerated pace.
How Syngene helped Panbela achieve shorter production time for its pancreatic cancer drug
Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing